Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPUCCI: FYB202 vs Stelara in Moderate-to-Severe Plaque Psoriasis
NCT04595409Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of ustekinumab-aauz in plaque psoriasis, sponsored by Bioeq AG. Started Nov 2020; status: completed.
02
Drugs
ustekinumab-aauz
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04595409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595409.